Methods for reducing the risk of an adverse drug interaction in a patient suffering from insomnia

Abstract

Disclosed herein is a method for treating a patient with Quazepam that reduces the risk of an adverse interaction between the Quazepam and drug that is a substrate of the cytochrome P450 enzyme isoform 2B6 (CYP2B6 substrate drug), e.g., Bupropion. The method includes determining if the patient to be treated with Quazepam is being treated with a CYP2B6 substrate drug, and prescribing or treating the patient with Quazepam based on the determination.

1 - 5 . (canceled) 
   
   
       6 . A method for reducing the risk of an adverse drug interaction in a patient suffering from insomnia, comprising:
 determining if the patient identified as suffering from insomnia is being treated with a drug that is a substrate of the CYP2B6 enzyme to treat a second condition, and   (i) if the patient is being treated with a drug that is a substrate of the CYP2B6 enzyme:
 (a) prescribing or administering a therapeutically effective amount of Quazepam to treat the insomnia, and monitoring the patient for an adverse side effect associated with Quazepam or the drug that is a substrate of the CYP2B6 enzyme; or 
 (b) stopping treatment with the drug that is a substrate of the CYP2B6 enzyme, and prescribing or administering a therapeutically effective amount of Quazepam to treat the insomnia; or 
   (ii) if the patient is not being treated with a drug that is a substrate of the CYP2B6 enzyme, prescribing or administering a therapeutically effective amount of Quazepam to treat the insomnia.   
   
   
       7 . The method of  claim 6 , wherein the patient is being treated with a drug that is a substrate of the CYP2B6 enzyme, comprising prescribing or administering a therapeutically effective amount of Quazepam to treat the insomnia, and monitoring the patient for an adverse side effect associated with Quazepam or the drug that is a substrate of the CYP2B6 enzyme. 
   
   
       8 . The method of  claim 7 , further comprising reducing the dose of the drug that is a substrate of the CYP2B6 enzyme. 
   
   
       9 . The method of  claim 6 , wherein the patient is being treated with a drug that is a substrate of the CYP2B6 enzyme, comprising stopping treatment with the drug that is a substrate of the CYP2B6 enzyme, and prescribing or administering a therapeutically effective amount of Quazepam to treat the insomnia. 
   
   
       10 . The method of  claim 9 , further comprising prescribing or administering a drug that is not a substrate of the CYP2B6 enzyme to treat the second condition. 
   
   
       11 . The method of  claim 6 , wherein the patient is not being treated with a drug that is a substrate of the CYP2B6 enzyme, comprising prescribing or administering a therapeutically effective amount of Quazepam to treat the insomnia. 
   
   
       12 . The method of  claim 6 , wherein the drug that is the substrate of the CYP2B6 enzyme is Bupropion. 
   
   
       13 . The method of  claim 6 , wherein the drug that is the substrate of the CYP2B6 enzyme is Efavirenz. 
   
   
       14 . The method of  claim 6 , wherein the second condition is depression. 
   
   
       15 . The method of  claim 14 , further comprising prescribing or administering to the patient a therapeutically effective amount of an antidepressant drug other than Bupropion. 
   
   
       16 . The method of  claim 15 , wherein the antidepressant drug other than Bupropion is not a substrate of the CYP2B6 enzyme. 
   
   
       17 - 19 . (canceled)